Recent Updates
Recently added Catalysts
VKTX Positive Sentiment

Kathy Rouan, Ph.D.

Key Takeaway: Dr. Kathy Rouan brings nearly 30 years of experience in the pharmaceutical industry, most recently as senior vice president at GlaxoSmithKline. She has a strong background in clinical operations and project management, having led the approval of Arzerra for chronic lymphocytic leukemia. Dr. Rouan holds a Ph.D. in pharmaceutical sciences.
Price reaction · baseline $34.63 (2025-11-04 close) · hit pre-market · 5 other VKTX headline(s) in the window, move may be shared
day 0 close
+5.3%
day 1
+7.6%
day 3 · peak
+9.1%

Market Sentiment Analysis

POSITIVE FACTORS

  • Dr. Rouan has extensive experience in the pharmaceutical industry.
  • She has successfully led the development and approval of significant drugs.
  • Her leadership roles at GSK demonstrate her capability and expertise.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+53%
120-day peak, hindsight
Typical move
13.6%
average across 5 past catalysts
Cash runway
~11 mo
Medium dilution risk
Lead asset
VK2735
Phase 3 · Weight Loss

Full Press Release Details

Dr. Rouan has nearly 30 years of pharmaceutical industry experience and most recently served as senior vice president and head of Projects, Clinical Platforms and Sciences (PCPS) at GlaxoSmithKline (GSK). GSK’s PCPS encompasses the company’s global clinical operations, statistics and programming, clinical pharmacology, GCP quality, third party resourcing and project management functions and includes approximately 1,800 individuals in 20 countries. Dr. Rouan first joined GSK in 1989 with a background in pharmaceutical sciences, focusing on formulation development of protein pharmaceuticals. In 1993, she transitioned into project leadership and management becoming vice president and head of metabolism and pulmonary project management in 1999. In 2007, Dr. Rouan led the development, submission and approval of Arzerra® (ofatumumab) for refractory chronic lymphocytic leukemia. In 2012, she became head of biopharmaceutical development, assuming responsibility for delivery of GSK’s portfolio of biopharmaceutical medicines. In December 2013, Dr. Rouan was appointed senior vice president and head of research and development for Stiefel, GSK’s dermatology therapy area unit. Dr. Rouan earned a Ph.D. in pharmaceutical sciences from the University of Rhode Island and a B.Pharm. from the University of London.

Frequently Asked Questions

What is Dr. Kathy Rouan's experience in the pharmaceutical industry?

Dr. Rouan has nearly 30 years of experience in the pharmaceutical industry.

What significant drug did Dr. Rouan help develop?

She led the development and approval of Arzerra for chronic lymphocytic leukemia.

What roles did Dr. Rouan hold at GlaxoSmithKline?

She served as senior vice president and head of various departments at GSK.

What degrees does Dr. Rouan hold?

She earned a Ph.D. in pharmaceutical sciences and a B.Pharm.

Last updated: Nov 5, 2025